Novo Nordisk Gives Unclear Answer On Participation In Medicare Negotiations Round Two

By Maaisha Osman / March 3, 2025 at 7:15 PM

Novo Nordisk would not say whether it has agreed to participate in the second round of Medicare drug price negotiations under the Inflation Reduction Act, while reiterating to Inside Health Policy its position that CMS’ decision to group its selected GLP-1 drugs as a single item does not meet the requirements of the statute.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.